CRISPR Therapeutics AG (CRSP)
Health Care ยท Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG (CRSP) is listed on Nasdaq, where its shares have traded since October 19, 2016. SentiSense covers CRISPR Therapeutics AG in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances). Samarth Kulkarni is its chief executive officer. The company reports 393 employees, and its corporate website is www.crisprtx.com.
About CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Latest reported results
CRISPR Therapeutics AG reported revenue of $12.7 million for Q3 FY2026, up 1325.1% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 510 institutions reported holding CRSP, with 76.2 million shares worth $4.2 billion in aggregate. The largest reported holders were ARK Invest, BlackRock and Capital Group. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on CRSP
- CRSP sentiment: whether news and social coverage of CRISPR Therapeutics AG leans bullish or bearish, and the stories driving it.
- CRSP ownership: all 510 reporting institutions, plus insider and congressional trades.
- CRSP financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
Frequently asked questions
What does CRISPR Therapeutics AG do?
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics.
What sector is CRSP in?
SentiSense classifies CRISPR Therapeutics AG in the Health Care sector, and its Standard Industrial Classification is Biological Products, (No Diagnostic Substances).
Where does CRSP stock trade?
CRISPR Therapeutics AG (CRSP) is listed on Nasdaq, where its shares have traded since October 19, 2016.
Who is the CEO of CRISPR Therapeutics AG?
Samarth Kulkarni is the chief executive officer of CRISPR Therapeutics AG.